Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.

Chabot JA, Tsai WY, Fine RL, Chen C, Kumah CK, Antman KA, Grann VR.

J Clin Oncol. 2010 Apr 20;28(12):2058-63. doi: 10.1200/JCO.2009.22.8429. Epub 2009 Aug 17.

2.

[Gemcitabine and pancreatic cancer].

Prost P, Ychou M, Azria D.

Bull Cancer. 2002 Aug;89 Spec No:S91-5. Review. French.

PMID:
12449037
3.

Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials.

Xie J, Yuan J, Lu L.

Diagn Pathol. 2014 Nov 25;9:214. doi: 10.1186/s13000-014-0214-8. Review.

4.

Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer?

Zhang X, Huang HJ, Feng D, Yang DJ, Wang CM, Cai QP.

World J Gastroenterol. 2014 Dec 14;20(46):17648-55. doi: 10.3748/wjg.v20.i46.17648. Review.

5.

Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?

Walker EJ, Ko AH.

World J Gastroenterol. 2014 Mar 7;20(9):2224-36. doi: 10.3748/wjg.v20.i9.2224. Review.

6.

Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review.

Ritchie GE, Fernando M, Goldstein D.

Cancer Chemother Pharmacol. 2017 Jan;79(1):1-7. doi: 10.1007/s00280-016-3123-6. Epub 2016 Aug 6. Review.

PMID:
27497971
7.

A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs.

Carrato A, Falcone A, Ducreux M, Valle JW, Parnaby A, Djazouli K, Alnwick-Allu K, Hutchings A, Palaska C, Parthenaki I.

J Gastrointest Cancer. 2015 Sep;46(3):201-11. doi: 10.1007/s12029-015-9724-1. Review.

Supplemental Content

Support Center